An RCT to Evaluate Incidence, Cost and Clinical Outcomes Using 75 vs 100g. Screening Methods for Gestational Diabetes
What is the Optimal Method for Screening and Diagnosis of Gestational Diabetes? An RCT to Evaluate Incidence, Cost-Effectiveness and Clinical Outcomes Using Three Methods
1 other identifier
observational
5,800
1 country
1
Brief Summary
Diabetes in pregnancy or gestational diabetes (GDM) is a condition that, if left untreated, may lead to complications for the mother and her baby. It is still not known which is the best method to diagnosis GDM. The goal of this study is to compare three well-accepted methods for diagnosis of GDM (using either 75 g or 100 g in the glucose tolerance test) and determine which method is the easiest and least expensive to use in relation to the reference method used over the last 20 years. The goal is to see if they can equally predict the healthy outcome of the pregnant mother and her newborn.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2001
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2001
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2004
CompletedFirst Submitted
Initial submission to the registry
February 22, 2006
CompletedFirst Posted
Study publicly available on registry
February 24, 2006
CompletedOctober 18, 2006
September 1, 2005
February 22, 2006
October 17, 2006
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- all women presenting for glucose screening in pregnancy between January 2001 and June, 2004 at a tertiary care university hospital setting
You may not qualify if:
- insufficient knowledge of French or English; known diabetes; refusal to participate; error in protocol; not fasting when presenting for study test
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Royal Victoria Hospital, McGill University Health Centre
Montreal, Quebec, H3A 1A1, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sara J Meltzer, MD, FRCPC
McGill Unversity, Faculty of Medicine, Dept. of Medicine and Obstetrics and Gynecology
Study Design
- Study Type
- observational
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 22, 2006
First Posted
February 24, 2006
Study Start
January 1, 2001
Study Completion
September 1, 2004
Last Updated
October 18, 2006
Record last verified: 2005-09